Richard WJ Groen
Richard WJ Groen
VU Medical Center
Geverifieerd e-mailadres voor amsterdamumc.nl - Homepage
Titel
Geciteerd door
Geciteerd door
Jaar
Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma
MB Overdijk, S Verploegen, M Bögels, M van Egmond, JJL van Bueren, ...
MAbs 7 (2), 311-320, 2015
2662015
Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia
A Gutierrez, L Pan, RWJ Groen, F Baleydier, A Kentsis, J Marineau, ...
The Journal of clinical investigation 124 (2), 644-655, 2014
1402014
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
IS Nijhof, T Casneuf, J Van Velzen, B van Kessel, AE Axel, K Syed, ...
Blood 128 (7), 959-970, 2016
1362016
The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcγ receptor–mediated cross-linking
MB Overdijk, JHM Jansen, M Nederend, JJL van Bueren, RWJ Groen, ...
The Journal of Immunology 197 (3), 807-813, 2016
1322016
Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab
IS Nijhof, RWJ Groen, HM Lokhorst, B Van Kessel, AC Bloem, ...
Leukemia 29 (10), 2039-2049, 2015
1322015
Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma
RWJ Groen, WA Noort, RA Raymakers, HJ Prins, L Aalders, FM Hofhuis, ...
Blood, The Journal of the American Society of Hematology 120 (3), e9-e16, 2012
1112012
Preclinical evidence for the therapeutic potential of CD38-targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib
IS Nijhof, RWJ Groen, WA Noort, B van Kessel, R de Jong-Korlaar, ...
Clinical cancer research 21 (12), 2802-2810, 2015
1012015
Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma
EPM Tjin, RWJ Groen, I Vogelzang, PWB Derksen, MD Klok, HP Meijer, ...
Blood 107 (2), 760-768, 2006
992006
A rational strategy for reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization
E Drent, M Themeli, R Poels, R de Jong-Korlaar, H Yuan, J de Bruijn, ...
Molecular therapy 25 (8), 1946-1958, 2017
792017
Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
E Drent, RWJ Groen, WA Noort, M Themeli, JJL van Bueren, PWHI Parren, ...
Haematologica 101 (5), 616-625, 2016
722016
Non-canonical PRC1. 1 targets active genes independent of H3K27me3 and is essential for leukemogenesis
V van den Boom, H Maat, M Geugien, AR López, AM Sotoca, J Jaques, ...
Cell reports 14 (2), 332-346, 2016
702016
Transcriptional silencing of the Wnt-antagonist DKK1 by promoter methylation is associated with enhanced Wnt signaling in advanced multiple myeloma
KA Kocemba, RWJ Groen, H Van Andel, MJ Kersten, K Mahtouk, ...
PloS one 7 (2), e30359, 2012
672012
Monocytes and granulocytes reduce CD38 expression levels on myeloma cells in patients treated with daratumumab
J Krejcik, KA Frerichs, IS Nijhof, B van Kessel, JF van Velzen, AC Bloem, ...
Clinical Cancer Research 23 (24), 7498-7511, 2017
612017
Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease
A Garcia-Gomez, D Quwaider, M Canavese, EM Ocio, Z Tian, JF Blanco, ...
Clinical cancer research 20 (6), 1542-1554, 2014
542014
Establishing human leukemia xenograft mouse models by implanting human bone marrow–like scaffold-based niches
A Antonelli, WA Noort, J Jaques, B de Boer, R de Jong-Korlaar, ...
Blood, The Journal of the American Society of Hematology 128 (25), 2949-2959, 2016
512016
A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect
H Rozemuller, E van der Spek, LH Bogers-Boer, MC Zwart, V Verweij, ...
haematologica 93 (7), 1049-1057, 2008
492008
Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance
J Sanne, NWCJ van de Donk, MC Minnema, JH Huang, T Aarts-Riemens, ...
Clinical cancer research 19 (20), 5591-5601, 2013
472013
Targeting EXT1 reveals a crucial role for heparan sulfate in the growth of multiple myeloma
RM Reijmers, RWJ Groen, H Rozemuller, A Kuil, A de Haan-Kramer, ...
Blood, The Journal of the American Society of Hematology 115 (3), 601-604, 2010
472010
Illegitimate WNT pathway activation by β-catenin mutation or autocrine stimulation in T-cell malignancies
RWJ Groen, MECM Oud, EJM Schilder-Tol, MB Overdijk, D ten Berge, ...
Cancer research 68 (17), 6969-6977, 2008
472008
Disruption of heparan sulfate proteoglycan conformation perturbs B-cell maturation and APRIL-mediated plasma cell survival
RM Reijmers, RWJ Groen, A Kuil, K Weijer, FC Kimberley, JP Medema, ...
Blood, The Journal of the American Society of Hematology 117 (23), 6162-6171, 2011
452011
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–20